IO Biotech Inc (IOBT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.00 (+100.00%), Market cap $0.00B, 52-week low–high $0.00 ~ $2.40.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arg
Financial statements, price targets, institutional (13F) holdings and related news for IO Biotech Inc are updated in real time on BlackAll Trade.
IO Biotech Inc trades at $0.00 (+100.00%). Real-time quotes and charts are available on BlackAll Trade.
IO Biotech Inc has a market cap of about $0.00B.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vacci